Gain Therapeutics, Inc. (GANX)

Market Cap	36.72M
Revenue (ttm)	210,660
Net Income (ttm)	-16.14M
Shares Out	11.88M
EPS (ttm)	-1.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,730
Open	3.08
Previous Close	3.07
Day's Range	3.06 - 3.1
52-Week Range	2.33 - 7.93
Beta	n/a
Analysts	Buy
Price Target	19.64 (+533.5%)
Earnings Date	Nov 11, 2022

About GANX

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B,...

• Industry: Biotechnology
• IPO Date: Mar 18, 2021
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: GANX

Full Company Profile

Financial Performance

In 2021, GANX's revenue was $164,994, an increase of 471.29% compared to the previous year's $28,881. Losses were -$13.89 million, 288.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for GANX stock is "Buy." The 12-month stock price forecast is 19.64, which is an increase of 533.55% from the latest price.

Price Target

$19.64

(533.55% upside)

Analyst Consensus: Buy

Stock Forecasts